Top

Published in:

01-04-2013 | Original Article

Orally Administered Phosphatidic Acids and Lysophosphatidic Acids Ameliorate Aspirin-Induced Stomach Mucosal Injury in Mice

Authors: Tamotsu Tanaka, Katsuya Morito, Masafumi Kinoshita, Mayumi Ohmoto, Mai Urikura, Kiyoshi Satouchi, Akira Tokumura

Published in: Digestive Diseases and Sciences | Issue 4/2013

Abstract

Background

Recent investigations revealed that lysophosphatidic acid (LPA), a phospholipid with a growth factor-like activity, plays an important role in the integrity of the gastrointestinal tract epithelium.

Aim

This paper attempts to clarify the effect of orally administered phosphatidic acid (PA) and LPA on aspirin-induced gastric lesions in mice.

Materials and Methods

Phospholipids, a free fatty acid, a diacylglycerol and a triglyceride at 1 mM (5.7 μmol/kg body weight) or 0.1 mM were orally administered to mice 0.5 h before oral administration of aspirin (1.7 mmol/kg). The total length of lesions formed on the stomach wall was measured as a lesion index. Formation of LPA from PA in the mouse stomach was examined by in vitro (in stomach lavage fluid), ex vivo (in an isolated stomach) and in vivo (in the stomach of a living mouse) examinations of phospholipase activity.

Results

Palmitic acid, dioleoyl-glycerol, olive oil and lysophosphatidylcholine did not affect the aspirin-induced lesions. In contrast, phosphatidylcholine (1 mM), LPA (1 mM) and PA (0.1, 1 mM) significantly reduced the lesion index. Evidence for formation of LPA from PA in the stomach by gastric phospholipase A₂ was obtained by in vitro, ex vivo and in vivo experiments. An LPA-specific receptor, LPA2, was found to be localized on the gastric surface-lining cells of mice.

Conclusion

Pretreatment with PA-rich diets may prevent nonsteroidal anti-inflammatory drug-induced stomach ulcers.

Moolenaar WH, van Meeteren LA, Giepmans BNG. The ins and outs of lysophosphatidic acid signaling. BioEssays. 2004;26:870–881.PubMedCrossRef

Tokumura A. Physiological significance of lysophospholipids that act on the lumen side of mammalian lower digestive tracts. J Health Sci. 2011;57:115–128.CrossRef

Sturm A, Sudermann T, Schulte K-M, Goebell H, Dignass AU. Modulation of intestinal epithelial wound healing in vitro and in vivo by lysophosphatidic acid. Gastroenterology. 1999;117:368–377.PubMedCrossRef

Deng W, Balazs L, Wang D-A, van Middlesworth L, Tigyi G, Johnson LR. Lysophosphatidic acid protects and rescues intestinal epithelial cells from radiation- and chemotherapy-induced apoptosis. Gastroenterology. 2002;123:206–216.PubMedCrossRef

Deng W, Shuyu E, Tsukahara R, et al. The lysophosphatidic acid type 2 receptor is required for protection against radiation-induced intestinal injury. Gastroenterology. 2007;132:1834–1851.PubMedCrossRef

Adachi M, Horiuchi G, Ikematsu N, et al. Intragastrically administered lysophosphatidic acid protect against gastric ulcer in rats under water-immersion restraint stress. Dig Dis Sci. 2011;56:2252–2261.PubMedCrossRef

Li C, Dandridge KS, Di A, et al. Lysophosphatidic acid inhibits cholera toxin-induced secretory diarrhea through CFTR-dependent protein interactions. J Exp Med. 2005;202:975–986.PubMedCrossRef

Singla A, Dwivedi A, Saksena S, et al. Mechanisms of lysophosphatidic acid (LPA) mediated stimulation of intestinal apical Cl⁻/OH⁻ exchange. Am J Physiol Gastrointest Liver Physiol. 2010;298:G182–G189.PubMedCrossRef

Singla A, Kumar A, Priyamvada S, et al. LPA stimulates intestinal DRA gene transcription via LPA2 receptor, PI3 K/AKT, and c-Fos-dependent pathway. Am J Physiol Gastrointest Liver Physiol. 2012;302:G618–G627.PubMedCrossRef

10.

Okudaira S, Yukiura H, Aoki J, et al. Biological roles of lysophosphatidic acid signaling through its production by autotaxin. Biochimie. 2010;92:698–706.PubMedCrossRef

11.

Sugiura T, Nakane S, Kishimoto S, Waku K, Yoshioka Y, Tokumura A. Lysophosphatidic acid, a growth factor-like lipid, in the saliva. J Lipid Res. 2002;43:2049–2055.PubMedCrossRef

12.

Tanaka T, Horiuchi G, Matsuoka M, et al. Formation of lysophosphatidic acid, a wound-healing lipid, during digestion of cabbage leaves. Biosci Biotechnol Biochem. 2009;73:1293–1300.PubMedCrossRef

13.

Tanaka T, Kassai A, Ohmoto M, et al. Quantification of phosphatidic acid in foodstuffs using a thin-layer-chromatography-imaging technique. J Agric Food Chem. 2012;60:4156–4161.PubMedCrossRef

14.

Taha AS, McCloskey C, Prasada R, Bezlyak V, et al. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomized, double-blind, placebo-controlled trial. Lancet. 2009;374:119–125.PubMedCrossRef

15.

Wallace JL. Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn’t the stomach digest itself? Physiol Rev. 2008;88:1547–1565.PubMedCrossRef

16.

Musumba C, Pritchard DM, Pirmohamed M. Cellular and molecular mechanisms of NSAID-induced peptic ulcers. Aliment Pharmacol Ther. 2009;30:517–531.PubMedCrossRef

17.

Lichtenberger LM, Barron M, Marathi U. Association of phosphatidylcholine and NSAIDs as a novel strategy to reduce gastrointestinal toxicity. Drugs Today. 2009;45:877–890.PubMed

18.

Tomisato W, Tanaka K, Katsu T, et al. Membrane permeabilization by non-steroidal anti-inflammatory drugs. Biochem Biophys Res Commun. 2004;323:1032–1039.PubMedCrossRef

19.

Maity P, Bindu S, Dey S, et al. Indomethacin, a non-steroidal anti-inflammatory drug, develops gastropathy by inducing reactive oxygen species-mediated mitochondrial pathology and associated apoptosis in gastric mucosa. J Biol Chem. 2009;284:3058–3068.PubMedCrossRef

20.

Somasundaram S, Rafi S, Hayllar J, et al. Mitochondrial damage: a possible mechanism of the “topical” phase of NSAID induced injury to the rat intestine. Gut. 1997;41:344–353.PubMedCrossRef

21.

Tomisato W, Tsutsumi S, Hoshino T, et al. Role of direct cytotoxic effects of NSAIDs in the induction of gastric lesions. Biochem Pharmacol. 2004;67:575–585.PubMedCrossRef

22.

Tanaka T, Tsutsui H, Hirano K, Koike T, Tokumura A, Satouchi K. Quantitative analysis of lysophosphatidic acid by time-of-flight mass spectrometry using a phosphate-capture molecule. J Lipid Res. 2004;45:2145–2150.PubMedCrossRef

23.

Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:911–917.PubMedCrossRef

24.

Chalvardjian A, Rudnicki E. Determination of lipid phosphorus in the nanomolar range. Anal Biochem. 1970;36:225–230.PubMedCrossRef

25.

Inoue M, Adachi M, Shimizu Y, Tsutsumi T, Tokumura A. Comparison of lysophospholipid levels in rat feces with those in a standard chow. J Agric Food Chem. 2011;59:7062–7067.PubMedCrossRef

26.

Morishige J, Urikura M, Takagi H, et al. A clean-up technology for the simultaneous determination of lysophosphatidic acid and sphingosine-1-phosphate by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry using a phosphate-capture molecule, Phos-tag. Rapid Commun Mass Spectrom. 2010;24:1075–1084.PubMedCrossRef

27.

Tanaka K, Tomisato W, Hoshino T, et al. Involvement of intracellular Ca²⁺ levels in nonsteroidal anti-inflammatory drug-induced apoptosis. J Biol Chem. 2005;280:31059–31067.PubMedCrossRef

28.

Dunjic BS, Axelson J, Ar’rajab A, Larsson K, Bengmark S. Gastroprotective capacity of exogenous phosphatidylcholine in experimentally induced chronic gastric ulcers in rats. Scand J Gastroenterol. 1993;28:89–94.PubMedCrossRef

29.

Holm BA, Keicher L, Liu M, Sokolowski J, Enhorning G. Inhibition of pulmonary surfactant function by phospholipases. J Appl Physiol. 1991;71:317–321.PubMed

30.

Lichtenberger LM, Wang Z-M, Romero JJ, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nature Med. 1995;1:154–158.PubMedCrossRef

31.

He D, Natarajan V, Stern R, et al. Lysophosphatidic acid-induced transactivation of epidermal growth factor receptor regulates cyclo-oxygenase-2 expression and prostaglandin E₂ release via C/EBP β in human bronchial epithelial cells. Biochem J. 2008;412:153–162.PubMedCrossRef

32.

Murph MM, Liu W, Yu S, et al. Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis. PLoS ONE. 2009;4:e5583.PubMedCrossRef

33.

Tojo H, Ying Z, Okamoto M. Purification and characterization of guinea pig gastric phospholipase A₂ of the pancreatic type. Eur J Biochem. 1993;215:81–90.PubMedCrossRef

34.

Uthe JF, Magee WL. Phospholipase A₂: action on purified phospholipids as affected by deoxycholate and divalent cations. Can J Biochem. 1971;49:776–784.PubMedCrossRef

35.

Foster DA. Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells. Biochim Biophys Acta. 2009;1791:949–955.PubMedCrossRef

36.

Cheney G. Rapid healing of peptic ulcers in patients receiving fresh cabbage juice. Calif Med. 1949;70:10–15.PubMed

Title: Orally Administered Phosphatidic Acids and Lysophosphatidic Acids Ameliorate Aspirin-Induced Stomach Mucosal Injury in Mice
Authors: Tamotsu Tanaka
Katsuya Morito
Masafumi Kinoshita
Mayumi Ohmoto
Mai Urikura
Kiyoshi Satouchi
Akira Tokumura
Publication date: 01-04-2013
Publisher: Springer US
Published in: Digestive Diseases and Sciences / Issue 4/2013
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-012-2475-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Aim

Materials and Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2013

A Great Masquerader: Acute Syphilitic Hepatitis

Risk Factors of Organ Failure in Patients with Bacteremic Cholangitis

Half-Dose Rabeprazole Has an Equal Efficacy to Standard-Dose Rabeprazole on Endoscopic Submucosal Dissection-Induced Ulcer

Role of Phospholipids in Protection of the GI Mucosa

The Down-Regulation of Notch1 Inhibits the Invasion and Migration of Hepatocellular Carcinoma Cells by Inactivating the Cyclooxygenase-2/Snail/E-cadherin Pathway In Vitro

Quality Improvement Measures Lead to Higher Surveillance Rates for Hepatocellular Carcinoma in Patients with Cirrhosis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials